Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary…
Alnylam Pharmaceuticals announced updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting…
Read More...
Read More...
